Prochymal

Phase 2Small molecule

MMesoblast, Ltd.

Prochymal is one of 142 small molecule programs targeting Acute Myocardial Infarction. It is currently in Phase 2.

Indications

Total Trials

Active Trials

141

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute Myocardial InfarctionActive, not recruiting

Acute Graft Versus Host DiseaseActive, not recruiting

Chronic Obstructive Pulmonary DiseaseActive, not recruiting

Type 1 Diabetes MellitusActive, not recruiting

Acute Myocardial InfarctionPhase 2

Active, not recruiting

Acute Graft Versus Host DiseasePreclinical

Active, not recruiting

Chronic Obstructive Pulmonary DiseasePhase 2

Active, not recruiting

Type 1 Diabetes MellitusPhase 2

Active, not recruiting

Competition

Competitive Landscape

557 competitors in Chronic Obstructive Pulmonary Disease

#DrugCompanyPhaseTrials

Prochymal

MMesoblast, Ltd.

Phase 2

1 2

Spiriva

Boehringer Ingelheim

Preclinical

15 3

Aclidinium Bromide

AstraZeneca

Preclinical

21 4

Formoterol Fumarate

AstraZeneca

Preclinical

11 5

Atrovent

Boehringer Ingelheim

Preclinical

5 6

Calciferol

Alnylam Pharmaceuticals

Preclinical

—7

Proventil

Mylan Pharmaceuticals Inc

Preclinical

3 8

Zoloft

VViatris Specialty LLC

Preclinical

1 9

Insulin Therapy

Sanofi

Preclinical

1 10

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Acute Graft Versus Host Disease4 trials

Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)

Completed·MMesoblast, Ltd.·Phase 3·NCT00366145·260 enrolled

Prochymal® Expanded Access for Adults Who Have Failed Steroid Treatment for Acute Graft Versus Host Disease (GVHD)

No longer available·MMesoblast, Ltd.··NCT00826046

Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)

Completed·MMesoblast, Ltd.·Phase 2·NCT00136903·32 enrolled

Show 1 more trial

Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)

Completed·MMesoblast, Ltd.·Phase 3·NCT00562497·192 enrolled

Crohn's Disease3 trials

Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease

Completed·MMesoblast, Ltd.·Phase 3·NCT00482092·330 enrolled

Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease

Completed·MMesoblast, Ltd.·Phase 3·NCT00543374·98 enrolled

Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease

Completed·MMesoblast, Ltd.·Phase 3·NCT01233960·73 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants

Completed·MMesoblast, Ltd.·Phase 2·NCT00284986·11 enrolled

Chronic Obstructive Pulmonary Disease1 trial

PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Completed·MMesoblast, Ltd.·Phase 2·NCT00683722·62 enrolled

Treatment Outcome1 trial

Safety and Treatment Outcome Study of PROCHYMAL® (Remestemcel-L) Intravenous Infusion in Subjects With Treatment-resistant Crohn's Disease

No longer available·MMesoblast, Ltd.··NCT01510431

3 more indications

Mesenchymal Stem Cells1 trial

Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease

Completed·MMesoblast, Ltd.·Phase 2·NCT00294112·10 enrolled

Acute Myocardial Infarction1 trial

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

Completed·MMesoblast, Ltd.·Phase 2·NCT00877903·220 enrolled

Type 1 Diabetes Mellitus1 trial

PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

Completed·MMesoblast, Ltd.·Phase 2·NCT00690066·63 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for Prochymal. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Prochymal compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Prochymal. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mesoblast, Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: MMesoblast, Ltd.

Prochymal

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Acute Graft Versus Host Disease4 trials

Crohn's Disease3 trials

Safety and Efficacy1 trial

Chronic Obstructive Pulmonary Disease1 trial

Treatment Outcome1 trial

Mesenchymal Stem Cells1 trial

Acute Myocardial Infarction1 trial

Type 1 Diabetes Mellitus1 trial

References

Drug Info

Quick Facts

Related News